During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering immunotherapy for gastric cancer.
Combination Immunotherapy and Chemotherapy Used in GI Cancers
During a live event, Yelena Y. Janjigian, MD, moderated a discussion on which frontline treatment to give a 60-year-old patient with stage IV gastric adenocarcinoma.
David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population.
Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.
David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
During a Case-Based Roundtable® event, David Zhen, MD, discussed the issue of treating patients with upper gastrointestinal cancer with a PD-L1 composite positive score less than 5 with nivolumab vs chemotherapy alone, in the first article of a 2-part series.
In a discussion with Targeted Oncology, Michael Gibson, MD, PhD, discusses the benefits of using a patient’s PD-L1 combined positive score to determine if they are given nivolumab and chemotherapy to treat their gastric cancer.
During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed the addition of nivolumab to chemotherapy for patients with gastric/gastroesophageal junction cancer based on PD-L1 status. This is the second of 2 articles based on this event.
During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed with participants their impressions of the CheckMate 649 chemoimmunotherapy regimen for patients with gastric/gastroesophageal junction cancers. This is the first of 2 articles based on this event.
Jaffer A. Ajani, MD, discusses the design and results of the CheckMate 649 study of nivolumab, ipilimumab, and chemotherapy for gastric cancers.